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Abstract The cholera toxin A-subunit (CTA) was genetically 
engineered at its amino end and tested for carriage of epitopes by 
fusion of the STa heat-stable enterotoxin analogue CAELCCN-
PAC. Efficient holotoxin formation by complementation in trans 
with cholera toxin B-subunit (CTB) indicated no decrease in 
affinity for CTB but evidence of reduced toxicity suggests steric 
interference by the decapeptide with the active site. The 
holotoxin was stable, able to bind to GM1 and was recognized 
by anti-STa and anti-CTA antibodies. The use of a full-length 
CTA might have been a key step for successful genetic fusions. 
Based on these findings, it seems worthwhile pursue the 
development of CTA for construction of recombinant mucosal 
immunoadjuvants. 
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1. Introduction 
Vibrio cholerae, the causative agent of cholera, induces in-
testinal fluid secretion by releasing several active virulence 
factors including the powerful cholera toxin (CT) [1]. This 
protein is a prototype enterotoxin made up of five copies of 
a B-subunit (CTB), required for binding to GM1 ganglioside 
[2] in the intestinal cell and one copy of an A-subunit (CTA) 
[3] which catalyzes the ADP-ribosylation of the Gs compo-
nent of adenylate cyclase in the target cell [4]. In the CT 
holotoxin the homopentameric CTB holds CTA in its center 
by non-covalent interactions [3]. CT has been crystallized and 
its three-dimensional model has been worked out [5]. The 
model for CT closely resembles that of its structural and func-
tional homologue, the heat-labile enterotoxin (LT) of Escheri-
chia coli [6]. The A-subunit of CT is synthesized as a single 
polypeptide chain post-translationally cleaved at or near resi-
due 192 to give fragments designated CTA1 (1-192) and 
CTA2 (192-240) [7]. Fragment CTA1 is the enzymatically 
active portion of the A-subunit while CTA2 mediates associa-
tion between CTA and pentameric CTB [8]. By mechanisms 
that have yet to be clarified, CT is a potent immunoadjuvant 
which stimulates mucosal immune responses against co-admin-
istered or coupled antigens [9,10]. Although CTB boosts im-
mune reactions it seems that much of the immunoadjuvantic-
ity of CT is due to CTA [10-13]. This work explored whether 
CTA could be made amenable to genetic fusion of peptides to 
eventually harness its natural immunoadjuvanticity. By geneti-
cally engineering the amino end of CTA, carriage of an en-
terotoxin antigen [14] was accomplished. The results presented 
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here may provide an approach to the development of CTA for 
the production of recombinant mucosal immunoadjuvants. 
2. Materials and methods 
2.1. Bacterial strains and cultures 
Competent DH5a or electrocompetent DH10B E. coli were pur-
chased commercially (Gibco BRL). When required, strains were 
made competent and transformed via CaCl/RbCl procedures [15]. E. 
coli S17-1 [16] was used to conjugate plasmids derived from pJS162 
[17]. All strains were kept in 20% glycerol at — 70°C and thawed the 
day before use. Liquid LB [15] cultures were carried out overnight at 
37°C with continuous orbital shaking. Recombinant clones were se-
lected on ampicillin at 100 ug/ml and/or chloramphenicol at 25 ug/ml. 
When required X-gal (Boehringer-Mannheim) at 125 ug/ml was in-
cluded in the plates. For expression by tacP, IPTG at 100 |xg/ml was 
added to cultures. 
2.2. DNA manipulations 
Restriction and ligation enzymes and Taq Polymerase were pur-
chased from Gibco-BRL, New England Biolabs, Promega, Boehrin-
ger-Mannheim or Perkin Elmer and used according to the manufac-
turers' instructions. Plasmid was isolated using a kit (Wizard 
miniprep, Promega) or by CsCl/EtBr gradients [15]. Plasmid electro-
poration (Cell-Porator, Gibco BRL) was performed following the 
manufacturer's instructions. Amplifications were in a PTC-1 cycler 
(Gibco-BRL). Synthetic primers were obtained from Genosys, Inc. 
Plasmid pVCD15 [18] used to amplify the CTA gene was generously 
provided by Dr. Jim Kaper (CVD, University of Maryland). The 5' 
end primer, 5'GTCGAAGAATTCACGGAGCTCCCGGGCAGA-
TTCCAGACCTCCTGATGAAATAAAG3', eliminated the Xbal 
site in the CTA gene [18] and incorporated EcoRl, Sacl and Xmal 
sites. The 3' end primer, 5'GTAAAAAAAACACCAAAGCTTAAT-
TTAATCATAATTCATCC3', added a Hindlll site after the stop 
codon (TGA). The amplicon was digested with EcoRl and Hindlll 
and cloned into pUC19. Oligonucleotides to restore the first 6 amino 
acids in CTA were joined at the Sacl and Xmal sites for subcloning 
and subsequent insertion into Sacl-Hindlll cut pJS162 [17] to give 
plasmid pRA003. Plasmid pJS384, for complementation by CTB, 
was created by insertion of a pJS752-3 [19] BamHl-Hindlll fragment, 
carrying the CTB gene and tacP, into plasmid pACYC184 [20]. Fu-
sion of decapeptide to CTA was carried out by ligation of synthetic 
oligonucleotides (Fig. IB) to Sacl restricted pRA003 to obtain plas-
mid pRA003-STd. The latter was introduced into E. coli SI7-1 and 
conjugally transferred to E. coli DH5a carrying pJS384. 
2.3. Immunological techniques 
Culture supernatants of E. coli carrying pJS384 plus pRA003-STd 
were 20-fold concentrated by ultrafiltration on YM-10 Amicon mem-
branes (Amicon Inc.). 50-JJ.I aliquots or 5 ug of purified CTA (Cal-
biochem) were boiled and run on SDS-PAGE [14]. Proteins were 
electrotransferred (Bio-Rad, MiniProtean System) to nitrocellulose 
membranes (Bio-Rad) for incubation with anti-CTA [21] or anti-
STa [22] monoclonal antibodies followed by goat anti-mouse IgG-
peroxidase conjugate (Gibco-BRL) and development with a-chloro-
naphthol substrate. GM1 ELISA [14] was used to assay recombinant 
CT or holotoxin with the decapeptide-CTA. 
2.4. Heal loop experiments 
E. coli culture supernatants containing the decapeptide-CTA holo-
toxin were investigated by using the ileal loop assay [23], 4-5 cm ileal 
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loops were prepared in two 2-3 kg adult male albino rabbits. Super-
natants were injected in 1 ml volumes. After 16 h the fluid inside the 
loops was recovered and measured. The ratio of the collected volume 
(ml) over the loop length (cm) was used to assess toxicity. Cholera 
toxin (List Biologicals) at 0.1 ug/ml in PBS was used as a positive 
control. 
3. Results and discussion 
3.1. Engineering of CTA 
Amplification of the CTA gene and cloning under tac? in 
plasmid pJS162 [17] joined full-length CTA to LTB leader 
peptide and incorporated a SacI site at the junction (Fig. 
1A) for genetic fusions. The cloned CTA assembled into ho-
lotoxin (not shown) when complemented by CTB encoded by 
plasmid PJS384. In contrast, a holotoxin where CTA had its 
first 6 amino acids replaced by LQSSRA was not obtained 
despite numerous genetic engineering strategies. The presence 
of free CTA antigen in whole cell sonicates shown by immu-
noblot assays (not shown) indicated failure to associate with 
CTB as seen for mutations in residue 114 in CTA [24]. Since 
none of the two regions interacts with CTA2 in the final toxin 
[5], one can postulate that replacements have an effect on 
either periplasmic holotoxin assembly [25,26] or periplasmic 
translocation as observed after deletion of CTA residues 6-13 
[27]. 
3.2. Genetic fusion of decapeptide to CTA 
Fusions to CTA are stimulated by the potential to develop 
mucosal antigens where its immunoadjuvanticity would be 
harnessed [28]. The peptide CAELCCNPAC is a non-toxic 
analogue of the sequence CCELCCNPAC found within the 
13 amino acid toxic moiety of STa heat-stable enterotoxins 
[29]. This decapeptide has turned out to be immunogenic after 
its genetic fusion to CTB [19] and was thus deemed to be a 
suitable candidate for testing peptide carriage by CTA. Since 
substitution of residues 1-6 in CTA hampered holotoxin re-
covery, fusion was performed on the full-length CTA gene 
described (Section 3.1). After fusion CTA had an amino end 
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Fig. 2. Titration of CTA antigen in decapeptide-CTA holotoxin by 
GM1 ELISA [22]. Curves were constructed plotting optical density 
values (ordinate axis) obtained in a microplate reader against the re-
ciprocal of each 3-fold serial dilution (abscissa). Two independently 
isolated and cultured colonies expressing the decapeptide-CTA holo-
toxin (colonies 8 and 53) were tested. Cholera toxin at 10 ug/ml 
was used as a standard. The calculated concentration of decapep-
tide-CTA holotoxin using anti-CTA is 6-7 |xg/ml of holotoxin per 
ml of culture. 
tail of 16 amino acids which included the decapeptide (Fig. 
IB). This protein was designated decapeptide-CTA. After co-
expression with CTB holotoxin in E. coli supernatants ranged 
from 5 to 10 |xg/ml (Fig. 2). Sonicated cell pellets had about 
5 times more holotoxin (not shown) due to poor excretion of 
CT by E. coli [30]. The hybrid nature of decapeptide-CTA was 
demonstrated by development of a protein band of approx. 30 
kDa in immunoblots with either anti-STa or anti-CTA (Fig. 
3). This immunoreactive band was invariant in number upon 
reduction (not shown), indicating that the decapeptide-CTA 
was not cleaved at the CTA1-CTA2 junction as observed for 
CTA [31]. Moreover, this indicated no degradation of the 
M N K V K F Y V L F T A L L 
AATTCOOOATOAATTA ATG AAT AAA OTA AAA TTT TAT OTT TTA TTT ACG OCO TTA CTA 
S S L C A H O A P N D D K L Y R A D 
TCC TCT CTA TOT OCA CAC OOAGCTCCT AAT GAT GAT AAG TTA TAC COO GCA GAT 
SacI 
B 
S S L C A H G A S R C A E L C C N P 
TCC TCT CTA TGT GCA CAC GGA GCT TCTAGA TGC GCT GAA TTG TGT TGT AAT CCT 
Xbal 
GCA TGC CCA GCT CCT AAT GAT GAT AAO TTA TAC CGG GCA OAT 
Fig. 1. (A) Sequence of junction in cloned CTA after fusion to LTB 
leader peptide. Single-letter coded amino acids are shown above the 
DNA sequence. The arrow shows the native leader peptide cleavage 
site (14). Amino acids encoded by the SacI site (underlined) are in 
bold-face type. Synthetic oligonucleotides added to restitute amino 
acids in CTA are in bold. (B) Sequence of junction after fusion of 
decapeptide to CTA. The decapeptide is shown in bold type and 
larger font. Flanking amino acids which do not form part of CTA 
or decapeptide are in bold type and smaller font. The introduced 
Xbal site is underlined as is the proposed S/D. Synthetic oligonu-
cleotides are distinguished in bold from the cloned CTA sequence. 
CT17 ST1:3 
Fig. 3. Immunoblot of decapeptide-CTA in concentrated E. coli cul-
ture supernatants. A concentrated supernatant with decapeptide-
CTA holotoxin was electrophoresed and proteins electroblotted. 
Although CTB was present, membranes were reacted only with 
anti-CTA or anti-STa to demonstrate the hybrid nature of the deca-
peptide-CTA. A strong protein band for pentameric CTB was ob-
tained (not shown) with anti-CTB when non-boiled samples [17] 
were run. Arrows (kDa) indicate positions of reference proteins in a 
pre-stained molecular marker (Gibco-BRL). Identical aliquots were 
transferred to both membranes. Supernatant was loaded on the left 
and purified CTA (Calbiochem) on the right. The left membrane 
(CT17) was reacted with anti-CTA. The position of the left band, 
slightly larger than CTA on the right, is consistent with it being the 
decapeptide-CTA. The band below CTA is most probably residual 
CTA1 in the standard. The right membrane (ST1:3) was reacted 
with anti-STa. The single band developed comigrated with the pro-
tein developed by anti-CTA as expected for decapeptide-CTA. No 
reaction by CTA and CTA1 was observed here. 
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fusion protein perhaps due to protection by CTB [32]. Toxic-
ity estimates in rabbit ileal loops using 0.5-1 u.g/ml of deca-
peptide-CTA holotoxin gave negative 0.1 ml/cm ratios while 
0.1 ug/ml of pure CT gave positive 0.69 and 0.78 ml/cm ratios. 
This indicates 5-10-fold lower toxicity. Reduction in toxicity 
because of an unsplit decapeptide-CTA chain (above) seems 
unlikely, since this model is not dependent upon prior toxin 
nicking [33]. Instead, reduced toxicity could be due to steric 
interference with the spatially close C T A catalytic residues [5]. 
Immunological assays will help to determine whether the im-
munoadjuvant capacity has been preserved as in detoxified 
LTA mutants [34]. 
In conclusion, engineering at the amino end of C T A lead to 
the successful carriage of a 16 amino acid heterologous pep-
tide which included the enterotoxin analogue C A E L C C N -
PAC. Our results suggest that the use of a full-length protein 
may be a key step when trying to achieve peptide carriage by 
CTA. The C T A fusion protein was able to associate with CTB 
to form a stable holotoxin. Epitope addition leads to a CTA 
with reduced toxicity, suggesting that the added epitope inter-
feres with the active site in CTA. Based on these findings, it 
would seem rewarding to proceed further with developing the 
cholera toxin A-subunit as a molecular carrier to induce mu-
cosal immunity against bacterial and viral infections. 
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